This is quite surprising because BCL6-positivity is considered an indicator of longer PFS and OS in DLBCL patients undergoing R-CHOP therapy [36], but it is consistent with our findings of a negative correlation between PATZ1 and BCL6, which is in agreement with the role of PATZ1 in the negative regulation of its expression. Here, BCL6 is linked to diffuse large B-cell lymphoma.